Atlas Trials

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Clinical trial NCT01124734 · COMPLETED

Trial details

NCT number
NCT01124734
Sponsor
Milton S. Hershey Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2010-05-01
Primary completion
2017-07-18
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.